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Context: Monogenic partial lipodystrophy is a genetically heterogeneous disease where only
variants with specific genetic mechanisms are causative. Three heterozygous protein extending
frameshift variants in PLIN1 have been reported to cause a phenotype of partial lipodystrophy and
insulin resistance.
Objective: We investigated if null variants in PLIN1 cause lipodystrophy.
Methods: As part of a targeted sequencing panel test, we sequenced PLIN1 in 2208 individuals. We
also investigated the frequency of PLIN1 variants in the gnomAD database, and the type 2 diabetes
knowledge portal.
Results: We identified 6/2208 (1 in 368) individuals with a PLIN1 null variant. None of these
individuals had clinical or biochemical evidence of overt lipodystrophy. Additionally, 14/17,000
(1 in 1214) individuals with PLIN1 null variants in the type 2 diabetes knowledge portal showed no
association with biomarkers of lipodystrophy. PLIN1 null variants occur too frequently in gnomAD
(126/138,632; 1 in 1100) to be a cause of rare overt monogenic partial lipodystrophy.
Conclusions: Our study suggests that heterozygous variants that are predicted to result in PLIN1
haploinsufficiency are not a cause of familial partial lipodystrophy and should not be reported as
disease-causing variants by diagnostic genetic testing laboratories. This finding is in keeping with other
knownmonogenic causes of lipodystrophy, such as PPARG and LMNA, where only variants with specific
genetic mechanisms cause lipodystrophy. (J Clin Endocrinol Metab 103: 3225–3230, 2018)
Lipodystrophies are rare disorders characterized by apaucity of subcutaneous fat typically associated with
metabolic complications including insulin resistance,
diabetes mellitus (DM), hyperandrogenism in females,
fatty liver disease, and dyslipidemia (1–4).
Heterozygous protein extending frameshift variants in
PLIN1 have been reported to cause a phenotype of partial
lipodystrophy and insulin resistance (1). PLIN1 encodes
perilipin1, a lipid droplet coat protein predominantly
expressed in adipocytes. Gandotra et al. (1) identified two
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heterozygous protein-extending frameshift variants in
PLIN1 in three families with partial lipodystrophy and
insulin-resistant diabetes. Kozusko et al. (5) reported a
different heterozygous protein-extending frameshift
variant in two families with a similar phenotype.
With the decreasing cost of DNA sequencing, di-
agnostic genetic testing no longer focuses on screening
individual genes but assesses panels of genes or full
exomes in a single test. This type of test is extremely
useful for genetically heterogeneous conditions such as
lipodystrophy. This less selective approach relies on the
correct understanding from the literature of which var-
iants within the tested genes are truly pathogenic.
As part of a routine gene panel test for genes reported to
be causative of lipodystrophy and monogenic diabetes, we
sequenced PLIN1 in 1323 patients referred for Maturity
Onset Diabetes of the Young (MODY) testing. We sub-
sequently studied a further 885 patients with neonatal
diabetes or hyperinsulinismwhowere tested using the same
targeted gene panel. We also investigated the frequency of
PLIN1 null variants in 138,632 people in gnomAD (6) and
lipodystrophy and diabetes phenotypes in 17,000 in-
dividuals in the diabetes knowledge portal. Only three
specific PLIN1 variants have been reported to cause lip-
odystrophy; our aimwas to investigate if null variants in the
gene were associated with the same phenotype.
Materials and Methods
Recruitment and phenotyping of cohort
At the Royal Devon and Exeter Hospital, 2208 patients were
referred for genetic testing to the Molecular Genetics Labora-
tory. We initially studied 1323 patients with a clinical suspicion
ofMODY. Subsequently, we studied a further 410 patients with
hyperinsulinemic hypoglycemia and 475 patients with neonatal
diabetes. Clinical information was provided on a standardized
referral form by the clinician at the time of referral for genetic
testing, and additional follow-up was carried out for four
families. At follow-up, the patients and family members were
assessed based on the multisociety practice guidelines on
diagnosing lipodystrophy (7). These guidelines provide the
list of clinical features that increase suspicion of lipodystrophy.
The list contains the following features: generalized or re-
gional absence of body fat, failure to thrive (infants and chil-
dren), prominent muscles, prominent veins, severe acanthosis
nigricans, eruptive xanthomata, cushingoid/acromegaloid/
progeroid appearance, DM with high insulin requirements
($200 U/d or $2 U/kg/d or requiring U-500 insulin), severe
hypertriglyceridemia ($500 mg/dL with or without therapy
or $250 mg/dL despite diet and medical therapy), history of
acute pancreatitis secondary to hypertriglyceridemia, non-
alcoholic steatohepatitis in a nonobese individual, early-onset
cardiomyopathy, and polycystic ovary syndrome.
An insulinmeasurementwas obtained for the father of proband
1 using an Access Ultrasensitive Insulin assay run on a Beckman
Coulter Unicel DXI 800 Access Immunoassay System (normal
range, 13.0 to 161). Proband 4 had their insulinmeasured using an
Abbott Architect insulin reagent kit on an Abbott Architect
i2000SR (reference ,83 pmol/L). Reference ranges for the assays
were obtained from the laboratories that performed the assays.
A dual-energy x-ray absorptiometry (DEXA) scan was per-
formed on proband 4. This measures the fat distribution within
the body and allows the calculation of a fat mass ratio—the ratio
between the fat mass of the trunk and the lower limbs (8).
Genetic analysis
We sequenced PLIN1 (NM_002666.4) by targeted next
generation sequencing, as part of a gene panel test (method-
ology described previously) (9). The panel contains baits for
genes in which pathogenic variants are reported to cause a range
of pancreatic-linked phenotypes (including lipodystrophy,
monogenic diabetes, and hyperinsulinism); only those relevant
to the patient’s disease are reported. Each sample was se-
quenced with a minimum of 3.3 million reads and greater than
99% of targeted bases covered at 303 or higher. All PLIN1
variants were also confirmed by Sanger sequencing.
Results
The phenotype of patients with heterozygous
null variants in PLIN1 is not consistent with
overt lipodystrophy
We initially tested 1323 patients with a clinical sus-
picion of MODY of which four had a heterozygous null
Table 1. Details of PLIN1 Variants and Phenotypic Data for the Probands and Family Members in Our Cohort
Family ID 1 2 3 4
Relation Proband Father Proband Proband Proband Father
Sex Female Male Female Female Male Male
Age at study, y 12 48 25 31 10 44
Ethnicity Asian (Filipino), UK Asian (Filipino), UK Mixed (White and
Black African), UK
White, UK White, Australia White, Australia
c.Nomen NM_002666.4:
c.760del
NM_002666.4:
c.760del
NM_002666.4:
c.985C.T
NM_002666.4:
c.964-1G.A
NM_002666.4:
c.433del
NM_002666.4:
c.433del
p.Nomen p.Val254Trpfs*4 p.Val254Trpfs*4 p.Arg329* p.? p.Ala145Profs*75 p.Ala145Profs*75
Exon 6 6 8 8 5 5
Diagnosis DM Unaffected Renal agenesis DM DM Unaffected
(Continued)
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variant in PLIN1 (probands 1 to 4; Table 1 and Fig. 1).
We investigated data from a further 885 non-MODY
patients sequenced with the same genetic panel test, two
of whom had a heterozygous null variant in PLIN1
(probands 5 and 6; Table 1 and Fig. 1). All of these
variants are nonsense or frameshift variants. None of
these patients had symptoms of lipodystrophy. The
published patients with pathogenic PLIN1 variants had
dyslipidemia with hypertriglyceridemia (range from 2 to
147 mmol/L) (1, 5); all of the patients in our study
with variants in PLIN1 had triglyceride levels below
1.7 mmol/L. Proband 4, who has a genetic diagnosis of
GCK MODY due to a heterozygous pathogenic mis-
sense variant (p.Val182Met), had a fasting glucose of
7 mmol/L, fasting insulin of 20.8 pmol/L, and had a
DEXA scan showing his fat mass ratio is 0.52. Valerio
et al. (8) used DEXA to measure the fat mass ratio
of a cohort of patients with partial lipodystrophy
and showed that their mean ratio was 1.86 compared
with controls with a mean ratio of 0.93. However,
although these results demonstrate that the phenotype
of proband 4 is inconsistent with lipodystrophy, he is
only 10 years of age thus features could present later
and DEXA scans at this age cannot conclusively
exclude lipodystrophy.
Symptoms of familial partial lipodystrophy typically
present at puberty in women. Two of our probands were
over 18 years old and did not display the characteristic
fat displacement or have biochemical evidence of overt
lipodystrophy. Additionally, family member testing for
four probands identified the PLIN1 variant in an un-
affected parent and one sibling (Table 1). Three of the
parents had no overt symptoms of lipodystrophy at the
ages of 40, 44, and 46, and although the father of proband
1, 48 years old, showed impaired fasting glycemia with
high cholesterol level but normal fasting triglyceride and
high high-density lipoprotein levels, these results are not
consistent with severe overt lipodystrophy.
Null variants in PLIN1 were not associated
with biomarkers of lipodystrophy in an
independent cohort
The lack of an overt lipodystrophy phenotype in
patients with null variants in PLIN1 raised questions
over the pathogenicity of protein truncating variants in
this gene. We used the type 2 diabetes knowledge portal
to assess the association of PLIN1 to the biomarkers of
lipodystrophy (10). The type 2 diabetes knowledge portal
is a repository of 17,000 people who have been exome
sequenced and had certain phenotypes tested. There are
seven different PLIN1 null variants in 14 people, giving a
frequency of 1 in 1214. PLIN1 null variants were not
associated with higher fasting insulin, higher triglycer-
ide, higher low-density lipoprotein, or lower high-density
lipoprotein (Supplemental Table 1), indicating that these
individuals do not have overt lipodystrophy.
Null variants in PLIN1 are present at a frequency in
gnomAD which is higher than expected
In the publically available gnomAD database, 126/
138,632 (1 in 1100) people have heterozygous null
variants (6). PLIN1 is not well covered in all individuals
in gnomAD, so the true frequency could be even higher
(see Supplemental Fig. 1). The pLI constraint score for
loss of function intolerance is 0 for PLIN1, predicting
that these variants are tolerated based on their frequency
(6). These findings are not consistent with heterozy-
gous null variants causing overt lipodystrophy. How-
ever, there are no null variants in a homozygous state
in gnomAD.
Discussion
PLIN1 variants are unlikely to be pathogenic via a
mechanism of haploinsufficiency
We present six probands and five family members
who have null variants in PLIN1 but no phenotype of
Table 1. Details of PLIN1 Variants and Phenotypic Data for the Probands and Family Members in Our Cohort
(Continued)
5 6
Proband Brother Mother Proband Mother
Male Male Female Female Female
1 6 37 1 40
Arabic, Saudi Arabia Arabic, Saudi Arabia Arabic, Saudi Arabia White, Austria White, Austria
NM_002666.4:
c.768_770delinsTG
NM_002666.4:
c.768_770delinsTG
NM_002666.4:
c.768_770delinsTG
NM_002666.4:
c.1448_1466dup
NM_002666.4:
c.1448_1466dup
p.Leu257Glufs*39 p.Leu257Glufs*39 p.Leu257Glufs*39 p.Glu490Leufs*82 p.Glu490Leufs*82
6 6 6 9 9
HI HI Unaffected HI Unaffected
Abbreviation: HI, hyperinsulinemic hypoglycemia.
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lipodystrophy. Importantly, six of these individuals are
over 18 years old, when familial partial lipodystrophy is
expected to have presented, and four are over the age of
40 years old. We were able to obtain follow-up in-
formation for four families. Although it was not possible
to obtain full information on all of these individuals, we
have clear biochemical measures, such as triglycerides,
for several individuals demonstrating they are unlikely to
have severe lipodystrophy at the time of study (however,
proband 4 was only 10 years of age; thus, there is the
potential to develop symptoms at a later date). Another
limitation of our study is that all biochemistry parameters
were measured locally with different commercial assays.
We have limited information in our original cohorts on
all the features of lipodystrophy that have been proposed
by the multisociety practice guidelines (7). However, this
is not a concern in our study as all of the patients in the
cohort had undergone genetic testing for all the genes on
our panel, irrespective of their clinical features. This
robust analysis has made sure that we did not miss any
patients with variants in PLIN1. It is possible that al-
though PLIN1 heterozygous null variants do not appear
to cause the overt lipodystrophic phenotype described in
Gandotra et al. (1), they may cause a more subtle form of
the disease.
Familial partial lipodystrophy is estimated to have a
prevalence of approximately 3 in 1 million in the general
population (11). The frequency of null variants in the
gnomAD database is incompatible with the frequency of
lipodystrophy. The prevalence of familial partial lip-
odystrophy would need to be greater than 1 in 10,000 to
be consistent with null variants in PLIN1 causing the
Figure 1. Pedigrees of the families with PLIN1 null variants. ALP, alkaline phosphatase; ALT, alanine transaminase; BMI, body mass index; Dx,
diagnosed; GAD, glutamic acid decarboxylase autoantibodies; GCK, glucokinase; HbA1c, glycated hemoglobin; HI, hyperinsulinemic hypoglycemia;
HLD, high-density lipoprotein; LD, lipodystrophy; LDL, low-density lipoprotein; NR, normal range; WHO, World Health Organization.
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disorder (12). If these variants caused familial partial
lipodystrophy, then the disease would be expected to
affect 60,000 people in the United Kingdom. Addition-
ally, the type two knowledge portal provides a set of
individuals with a high frequency of PLIN1 variants
where there is no association with raised insulin or lipids.
Thus, variants in PLIN1 are unlikely to be acting via a
mechanism of true haploinsufficiency, i.e., complete lack
of one allele.
PLIN1 is an example of a gene where only variants
with specific genetic mechanisms are likely to
be pathogenic
There is a range of genetic mechanisms of pathoge-
nicity for the known monogenic causes of lipodystrophy.
For example, some variants in PPARG demonstrate
dominant negative behavior (2, 3), whereas others ap-
pear to be pathogenic due to haploinsufficiency. A
different pattern is observed in LMNA where hap-
loinsufficiency causes phenotypes including cardiomy-
opathy, whereas specific missense variants result in
lipodystrophy, and other specific mutations in LMNA
cause distinct phenotypes, including progeria (4).
The PLIN1 frameshift variants published as patho-
genic do not appear in gnomAD. However, it is also
possible that the reason we do not see these in gnomAD is
that the last exon has very low sequencing coverage: the
majority of samples have less than 103 coverage (see
Supplemental Fig. 1). The absence of the published
variants in gnomAD and our cohort prevents us from
commenting on their pathogenicity.
A possible explanation for the high frequency of
PLIN1 null variants in public databases would be that
variants are pathogenic but have low penetrance or
reduced clinical expressivity. However, given their
frequency, they would either need to have very low
penetrance or the disease would need to be more com-
mon than assumed (more common than 1 in 10,000).
PLIN1 variants resulting in haploinsufficiency should
not be reported as pathogenic without
further evidence
Doubt over haploinsufficiency in PLIN1 causing
lipodystrophy has important consequences for genetic
testing. PLIN1 is currently screened on diagnostic tar-
geted gene panel tests for lipodystrophy, insulin re-
sistance, and diabetes. We recommend that null variants
in PLIN1 should not be reported as causative of
lipodystrophy.
Our study suggests that heterozygous null variants in
PLIN1 do not cause overt lipodystrophy and provides
another example of a gene where only variants with
specific genetic mechanisms cause lipodystrophy.
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